Sero-epidemiology of Bordetella pertussis in England and Wales

Vaccine

Volumn 22, Issue 9-10, 2004, Pages 1314-1319

  Nardone, A ^a   Pebody, R G ^a   Maple, P A C ^a   Andrews, N ^a   Gay, N J ^a   Miller, E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Pertussis; Sero epidemiology; UK

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; TITRIMETRY; UNITED KINGDOM;

AGE FACTORS; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MASS IMMUNIZATION; MONITORING, IMMUNOLOGIC; PERTUSSIS TOXIN; PERTUSSIS VACCINE; WALES; WHOOPING COUGH;

EID: 1542301022     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.08.039     Document Type: Article

References (27)

1. Edwards KM, Decker MD, Mortimer EA. Pertussis vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Saunders: Philadephia/London/Toronto/ Montreal/Sydney/Tokyo; 1999.
2. Miller E, Gay NJ. Effect of age on outcome and epidmeiology of infectious diseases. Biologicals 1997;25:137-42.
3. Miller E, Gay NJ. Epidemiological determinants of pertussis. In: Brown F, Greco D, Mastroantonio P, Salmaso S, Wassilak S, editors. Pertussis vaccine trials. Dev Biol Stand. Basel: Krager; 1997;89:15-23.
4. Long S.S., Lischner H.W., Deforest A., Clark J.L. Serologic evidence of sub-clinical pertussis in immunized children. Pediatr. Infect. Dis. J. 9:1990;700-705.
5. Deville J.G., Cherry J.D., Christenson P.D.et al. Frequency of unrecognised Bordetella pertussis infections in adults. Clin. Infect. Dis. 21:1995;639-642.
6. Wirsing von Konig C.H., Postels-Multani S., Bock H.L.et al. Pertussis in adults: frequency of transmission after household exposure. Lancet. 346:1995;1326-1329.
7. Long S.S., Welkon C.J., Clark J.L.et al. Widespread silenty transmission of pertussis in families: antibody correlates of infection and symptomatology. J. Infect. Dis. 161:1990;480-486.
8. Miller E., Fleming D.M., Ashworth L.A.E.et al. Serological evidence of pertussis in patients presenting with cough in general practice in Birmingham. Commun. Dis. Public Health. 3:2000;132-134.
9. CDSC. Vaccine preventable diseases. In: 1999/2000 Review of communicable diseases. England and Wales. Available online at http://www.phls.org.uk/ publications/annual_review/Ch04.pdf.
10. Crowcroft N., Andrews N., Rooney C.et al. Deaths from pertussis are underestimated in England. Arch. Dis. Child. 86:2002;336-338.
11. Department of Health. Immunisation against infectious diseases 1990. London: HMSO; 1990.
12. PHLS. Addition of acellular pertussis to pre-school booster. CDR Wkly 2001;11:1-2.
13. de Melker H.E., Versteegh F.G.A., Conyn-van Spaendonck M.A.E.et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J. Clin. Microbiol. 38:2000;800-906.
14. Osborne K., Gay N., Hesketh L.et al. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int. J. Epid. 29:2000;362-368.
15. Giammanco A., Maple P.A.C., Andrews N. European Sero-Epidemiology Network: standardisation of assay results for pertussis. Vaccine. 22(1):2003;112-120.
16. PHLS. COVER programme: April to June 2002. Commun Dis Rep CDR Wkly [serial online] 2002 [cited 26 September 2002] 12: immunisation. Available online at http://www.hpa.org.uk/cdr/PDFfiles/2002/cdr3902.pdf.
17. Pebody RG, Gay N, Giammanco A, et al. The sero-epidemiology of pertussis in western Europe. Epidemiol Infect [submitted for publication].
18. Teunis P.F.M., van der Heijden O.G., de Melker H.E.et al. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol. Infect. 129:2002;479-489.
19. Strebel P., Nordin J., Edwards K.et al. Population-based incidence of pertussis amongst adolescents and adults Minnesota, 1995-1996. J. Infect. Dis. 183:2001;1353-1359.
20. Black S. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 16:1997;S85-S89.
21. Campins-Marti M., Cheng H.K., Forsyth K.et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine. 20:2002;641-646.
22. Cherry J.D. Pertussis in adults. Ann. Intern. Med. 128:1998;64-66.
23. Edmunds W.J., Brisson M., Melegaro A., Gay N.J. The potential cost-effectiveness of acellular booster vaccination in England and Wales. Vaccine. 20:2002;1316-1330.
24. Jenkinson D. Duration of the effectiveness of pertussis vaccination: evidence form a 10-year community study. BMJ. 296:1988;612-614.
25. Ramsay M.E.B., Farrington C.P., Miller E. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol. Infect. 111:1993;41-48.
26. Wilkins J., Chan L., Wehrle P. Age and dose interval as factors in agglutinnin formation to pertussis vaccine. Vaccine. 5:1987;49-54.
27. Van Buynder P.G., Vurdein J.E., Owen D.et al. Bordetella pertussis surveillance in England and Wales: 1995-1997. Epidemiol. Infect. 123:1999;403-411.